Oncology development hasn’t just become faster; it has become more complex and less forgiving of missteps. Sponsors are now expected to move quickly in early phase oncology development, then expand across cohorts, sites, and regions without hesitation. The science may be differentiated, but success now largely depends on whether programs can hold together as complexity grows. Unfortunately, this is where many sponsors lose momentum.
Why the Traditional Models Fall Short
This loss of momentum is a common stumbling block. Momentum stalls when early gains evaporate. Teams change, handoffs multiply, and coordination becomes a bottleneck. As a result, sponsors end up spending more time managing intricacies than advancing the therapy.
The impact extends to operational models as well. Generic CRO models were built for scale, not to maintain momentum as programs evolve. On the other hand, boutique oncology models deliver expertise for the earliest stages of development but often struggle when studies need to scale. Sponsors are left to navigate unnecessary trade-offs between speed and scale, even though both are required for any sort of success.
A Different Starting Assumption
Worldwide Clinical Trials’ oncology services were built on a different assumption; since oncology programs are complex and time-sensitive, there isn’t time to reset execution whenever the scope changes. Rather than stitching together expertise and scale as separate phases, Worldwide designed a global, oncology-specialized operating model. This model supports fast, confident early decisions and sustains momentum as programs grow.
Continuity by Design, Not by Chance
The core principle behind the model is continuity, which involves teams, so early momentum and decision context aren’t lost. It reaches data and oversight, where information must be interpreted consistently and accurately, which ultimately supports better, more continuous decision-making to keep progress moving even as the trial requires more nuanced protocols and operations.
When continuity is built into the model, sponsors spend less time re-onboarding, re-aligning, and re-explaining. As a result, decisions happen faster, with greater confidence, and programs move forward smoothly as they expand.
Built for the Full Oncology Journey
Worldwide’s oncology services bring together:
- Deep, oncology specialized expertise that drives confident early choices
- Designed for scale operations that anticipate expansion rather than react to it
- Sponsor aligned oversight that supports clarity without slowing progress
This isn’t a generic CRO with an oncology group, nor a boutique model that struggles to scale. Worldwide has an oncology-specific model designed to support programs from first-in-human through commercialization, alongside the program as it grows.
Why This Matters
Everything in the model exists for one reason, which is to help sponsors deliver life-changing oncology therapies to patients faster. In today’s environment, neither speed nor scale is sufficient in isolation, and programs that succeed are built on both, from the outset.
Continue the Conversation
Attending this year’s ASCO Annual Meeting? Meet with our team of experts to continue the conversation on scaling your oncology development and learn how we can meet your needs. Book a meeting today.
